| Literature DB >> 36079758 |
Magdalena Kiedrowicz1, Ewa Duchnik2, Jolanta Wesołowska2, Beata Bania3, Małgorzata Peregud-Pogorzelska3, Dominika Maciejewska-Markiewicz4, Ewa Stachowska4, Joanna Kruk5, Mariola Marchlewicz1.
Abstract
BACKGROUND: Abdominal obesity, together with atherogenic dyslipidemia, increased blood pressure and impaired glucose tolerance, was included in the components of metabolic syndrome identifying patients at high risk of cardiovascular diseases. Subcutaneous adipose tissue is a buffer for dietary fatty acids (FAs). It was reported that the fatty acid composition of adipose tissue reflects the dietary intake of FAs in the previous 6 to 9 months. Therefore, we decided to evaluate the early and long-term metabolic effects of lipocavitation and/or thermolipolysis on abdominal fat reduction.Entities:
Keywords: abdominal fat reduction; fatty acids; radiofrequency treatment; ultrasound treatment
Mesh:
Substances:
Year: 2022 PMID: 36079758 PMCID: PMC9459719 DOI: 10.3390/nu14173498
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1Study design (prepared using BioRender software).
The clinical, anthropometric and biochemical characteristics of the study population and the short and long-term effects of all interventions applied for an adipose tissue reduction.
| Parameters | Baseline | After 10 Treatments vs. Baseline |
| After 6 Months vs. Baseline |
|
|---|---|---|---|---|---|
| Age, years | 38 (33–42) | - | - | - | - |
| Height, cm | 167 (163–170) | - | - | - | - |
| Body weight, kg | 68 (63–75.3) | 67.3 (62–75.5) | 0.001 | 66.7 (59–74.1) | 0.005 |
| BMI, kg/m2 | 25 (22.5–28.3) | 24.7 (22.3–28) | 0.001 | 24.7 (22.4–27.9) | 0.005 |
| Waist circumference, cm | 82 (75–88) | 78 (74–85) | 0.001 | 78 (74–84) | 0.02 |
| Hip circumference, cm | 101 (96–105) | 100 (95–104) | 0.5 | 98 (94–103) | 0.3 |
| WHR | 0.81 (0.77–0.84) | 0.81 (0.77–0.83) | 0.9 | 0.81 (0.77–0.83) | 0.9 |
| HOMA | 2.0 (1.2–2.7) | 1.6 (1.2–2.5) | 0.1 | 1.9 (1.2–2.5) | 0.5 |
| QUICKI | 0.3 (0.3–0.4) | 0.3 (0.3–0.4) | 0.7 | 0.3 (0.3–0.4) | 0.7 |
| WBC, × 109/L | 6.1 (4.8–7.3) | 6.1 (5.1–7.0) | 0.8 | 6.1 (5.1–7.5) | 0.9 |
| CRP, mg/L | 1.1 (0.5–2.0) | 1.1 (0.4–2.0) | 0.8 | 1.1 (0.5–2.1) | 0.8 |
| Glucose, mg/dL | 92 (86–99) | 91 (85–96) | 0.6 | 90 (84–95) | 0.4 |
| Insulin, I.U. | 8.6 (5.5–11.5) | 7.1 (5.5–12.5) | 0.2 | 8.8 (5.4–11.4) | 0.6 |
| Total cholesterol, mg/dL | 197 (175–217) | 191 (172–215) | 0.3 | 196 (165–215) | 0.8 |
| LDL, mg/dL | 109 (90–127) | 106 (94–127) | 0.5 | 110 (91–132) | 0.9 |
| HDL, mg/dL | 59 (50–67) | 56 (50–65) | 0.6 | 60 (50–65) | 0.7 |
| TG, mg/dL | 76 (59–105) | 74 (58–111) | 0.7 | 83 (62–109) | 0.5 |
| Systolic pressure, mmHg | 110 (110–120) | 115 (105–120) | 0.2 | 115 (105–130) | 0.4 |
| Diastolic pressure, mmHg | 70 (60–80) | 70 (60–75) | 0.9 | 70 (65–80) | 0.9 |
Abbreviations: BMI, body mass index; WHR, waist to hip ratio; WBC, white blood cell; CRP, C-reactive protein; LDL, cholesterol; HDL, cholesterol plus triglycerides; TG, triglycerides; HOMA, homeostatic model assessment; QUICKI, quantitative insulin sensitivity check index; Differences were statistically significant at p < 0.05. All continuous variables are expressed as a median and interquartile range [Q1–Q3] as not normally distributed. The Shapiro–Wilk test was used to check if a continuous variable follows a normal distribution.
Inflammatory and biochemical parameters in the study population.
| Parameters | Baseline | 4 h After Treatment |
|
|---|---|---|---|
| WBC, ×109/L | 6.1 (4.8–7.3) | 7.3 (5.8–8.4) | 0.005 |
| CRP, mg/L | 1.1 (0.5–2.0) | 1.1 (0.5–2.0) | 0.7 |
| TC, mg/dL | 197 (175–217) | 196 (170–222) | 0.8 |
| HDL, mg/dL | 59 (50–67) | 60 (50–72) | 0.4 |
| LDL, mg/dL | 109 (90–127) | 107 (89–131) | 0.8 |
| TG, mg/dL | 76 (59–105) | 73 (57–93) | 0.5 |
Abbreviations are the same as under Table 1. All continuous variables are expressed as a median and interquartile range [Q1–Q3] as not normally distributed. The Shapiro–Wilk test was used to check if a continuous variable follows a normal distribution. Differences were statistically significant at p < 0.05.
Body weight of the studied women [kg].
| Treatment | Baseline | After 10 Treatments vs. Baseline |
| After 6 Months vs. Baseline |
|
|---|---|---|---|---|---|
| U | 63.3 (60–70) | 62.9 (58.8–68.7) | 0.01 | 62.5 (58–72.6) | 0.1 |
| RF | 69.75 (64–79.2) | 67.6 (63.5–78) | 0.0035 | 67.75 (63.8–77) | 0.04 |
| RF/U | 68 (64.5–82.8) | 67.75 (64.3–81.5) | 0.009 | 68.1 (62.5–80) | 0.3 |
Abbreviations: Destination U, group treated with ultrasound; RF, group treated using radiofrequency device. All continuous variables are expressed as a median and interquartile range [Q1–Q3] as not normally distributed. The Shapiro–Wilk test was used to check if a continuous variable follows a normal distribution. Differences were statistically significant at p < 0.05.
BMI in the studied women [kg/m2].
| Treatment | Baseline | After 10 Treatments vs. Baseline |
| After 6 Months vs. Baseline |
|
|---|---|---|---|---|---|
| U | 23.7 (22.3–25.6) | 23.3 (22.2–25.3) | 0.02 | 23.1 (22.1–25.5) | 0.2 |
| RF | 25.7 (23.3–30.4) | 25.2 (23.2–30) | 0.002 | 25.1 (23.2–30) | 0.03 |
| RF/U | 26.1 (22–28.6) | 25.9 (22–28.7) | 0.003 | 25.3 (21.6–29.8) | 0.4 |
Designation is the same as under Table 3. All continuous variables are expressed as a median and interquartile range [Q1–Q3] as not normally distributed. The Shapiro–Wilk test was used to check if a continuous variable follows a normal distribution. Differences were statistically significant at p < 0.05.
Waist circumference of the studied women [cm].
| Treatment | Baseline | After 10 Treatments vs. Baseline |
| After 6 Months vs. Baseline |
|
|---|---|---|---|---|---|
| U | 78.5 (75–88) | 78 (74–85) | NS | 78 (73–84) | 0.9 |
| RF | 82.5 (77–92) | 78.5 (75–86) | 0.008 | 78.5 (76–83) | 0.04 |
| RF/U | 82 (76–85) | 77 (75–83) | 0.02 | 76 (74–83) | 0.5 |
Designation is the same as under Table 3. All continuous variables are expressed as a median and interquartile range [Q1–Q3] as not normally distributed. The Shapiro–Wilk test was used to check if a continuous variable follows a normal distribution. Differences were statistically significant at p < 0.05.
Content of fatty acids in the blood [ug/mL].
| Time Point | FFAs [ug/mL] | Before | 1 h After | 4 h After | After the Last Treatment | 6 Months After | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| U | C10:0 | 9 (7–15) | 9 (9–15) | 0.8 | 12 (7–16) | 0.09 | 14 (8–21) | 0.07 | 4 (2–9) | 0.06 |
| RF | 19 (12–27) | 16 (20–22) | 0.5 | 18 (12–25) | 0.7 | 23 (16–27) | 0.5 | 5 (3–9) | 0.013 | |
| RF/U | 8 (5–12) | 9 (7–16) | 0.9 | 9 (5–15) | 0.8 | 12 (8–16) | 0.6 | 10 (9–12) | 0.7 | |
| U | C12:0 | 4 (2–21) | 4 (2–59) | 0.6 | 12 (2–164) | 0.1 | 5 (3–263) | 0.5 | 5 (2–76) | 0.7 |
| RF | 27 (7–257) | 57(6–231) | 0.2 | 105 (12–288) | 0.03 | 31(15–277) | 0.09 | 63(10–120) | 0.2 | |
| RF/U | 3 (2–9) | 4 (2–17) | 0.7 | 4 (3–8) | 0.8 | 3 (3–10) | 0.7 | 3 (2–10) | 0.6 | |
| U | C14:0 | 8 (5–12) | 9 (7–16) | 0.6 | 9 (5–15) | 0.8 | 12 (8–16) | 0.7 | 10 (9–12) | 0.8 |
| RF | 10 (9–15) | 10 (9–13) | 0.7 | 10 (9–13) | 0.7 | 10(8–17) | 0.6 | 22 (12–23) | 0.3 | |
| RF/U | 17 (14–24) | 16 (10–19) | 0.9 | 15 (11–18) | 0.9 | 23 (17–26) | 0.5 | 17 (10–20) | 0.9 | |
| U | C15:0 | 4 (3–4) | 3 (3–4) | 0.4 | 3 (2–4) | 0.6 | 4 (3–17) | 0.7 | 3 (2–5) | 0.6 |
| RF | 2 (2–3) | 2 (2–3) | 0.8 | 2 (2–4) | 0.06 | 3 (2–3) | 0.1 | 5 (4–6) | 0.005 | |
| RF/U | 3 (2–4) | 2 (2–4) | 0.6 | 4 (2–5) | 0.3 | 4 (2–5) | 0.4 | 2 (2–4) | 0.6 | |
| U | C16:0 | 345 (275–474) | 352 (250–408) | 0.4 | 346 (302–390) | 0.6 | 414 (351–433) | 0.09 | 292 (241–353) | 0.03 |
| RF | 300 (243–350) | 320 (244–361) | 0.7 | 302 (236–318) | 0.7 | 283 (258–294) | 0.5 | 405 (278–445) | 0.2 | |
| RF/U | 384 (272–498) | 307 (277–411) | 0.8 | 424 (250–578) | 0.8 | 465 (344–587) | 0.5 | 382 (300–404) | 0.9 | |
| U | C16:1 | 22 (15–28) | 18 (8–27) | 0.6 | 22 (19–27) | 0.8 | 32 (20–40) | 0.1 | 15 (13–18) | 0.3 |
| RF | 15 (10–18) | 17 (14–35) | 0.8 | 19 (16–26) | 0.7 | 15(14–23) | 0.7 | 17 (12–21) | 0.8 | |
| RF/U | 22 (15–36) | 19 (12–32) | 0.8 | 14 (13–33) | 0.4 | 35 (18–44) | 0.5 | 22 (14–31) | 0.9 | |
| U | C17:0 | 6 (4–9) | 5 (4–9) | 0.5 | 4 (4–5) | 0.05 | 6 (4–8) | 0.6 | 4 (3–14) | 0.3 |
| RF | 5 (4–9) | 5 (4–6) | 0.6 | 5 (4–6) | 0.7 | 5(4–5) | 0.8 | 11 (5–16) | 0.07 | |
| RF/U | 5 (4–7) | 4 (3–8) | 0.7 | 6 (3–8) | 0.6 | 6 (4–8) | 0.7 | 4 (3–6) | 0.7 | |
| U | C18:0 | 148 (108–178) | 139 (103–153) | 0.8 | 147 (115–160) | 0.8 | 149 (143–245) | 0.8 | 132 (112–238) | 0.5 |
| RF | 130 (109–144) | 115 (97–141) | 0.7 | 127 (98–131) | 0.5 | 121(115–131) | 0.7 | 224 (144–270) | 0.046 | |
| RF/U | 172 (134–202) | 153 (123–198) | 0.3 | 173 (113–244) | 0.8 | 203 (153–234) | 0.4 | 153 (126–175) | 0.8 | |
| U | C18:1w9ct | 271 (162–363) | 223 (167–267) | 0.8 | 232 (205–269) | 0.5 | 258 (215–348) | 0.8 | 142 (104–185) | 0.01 |
| RF | 224 (165–252) | 207 (146–293) | 0.7 | 220(169–256) | 0.7 | 205(179–272) | 0.6 | 168 (138–218) | 0.1 | |
| RF/U | 285 (169–373) | 262 (176–315) | 0.7 | 324 (172–415) | 0.3 | 331 (237–423) | 0.5 | 272 (180–320) | 0.9 | |
| U | C18:1trans1 | 28 (23–41) | 23 (16–29) | 0.4 | 21 (21–26) | 0.6 | 28 (24–35) | 0.9 | 17 (13–23) | 0.03 |
| RF | 20 (15–27) | 21(15–31) | 0.7 | 20 (17–25) | 0.7 | 18(17–26) | 0.7 | 16 (16–17) | 0.3 | |
| RF/U | 28 (13–35) | 25 (15–28) | 0.8 | 30 (15–42) | 0.7 | 33 (21–36) | 0.7 | 24 (17–29) | 0.6 | |
| U | C18:2n6c | 281 (232–360) | 263 (200–349) | 0.6 | 278 (236–308) | 0.7 | 293 (230–401) | 0.6 | 202 (137–244) | 0.02 |
| RF | 299 (219–377) | 293 (236–361) | 0.8 | 296 (242–327) | 0.7 | 316(269–331) | 0.4 | 226 (201–279) | 0.08 | |
| RF/U | 348 (212–387) | 273 (192–343) | 0.5 | 306 (204–476) | 0.6 | 361 (308–461) | 0.7 | 284 (236–314) | 0.2 | |
| U | C18:3 | 4 (4–5) | 4 (2–4) | 0.7 | 3 (3–5) | 0.6 | 4 (3–7) | 0.7 | 3 (2–11) | 0.7 |
| RF | 4 (3–5) | 4 (3–4) | 0.8 | 4 (4–5) | 0.08 | 4(3–5) | 0.8 | 5 (4–10) | 0.03 | |
| RF/U | 4 (3–5) | 4 (3–5) | 0.7 | 4 (3–7) | 0.3 | 4 (3–6) | 0.4 | 4 (3–5) | 0.8 | |
| U | C20:4n6 | 84 (75–98) | 82 (67–91) | 0.9 | 84 (67–91) | 0.9 | 102 (81–138) | 0.3 | 47 (36–72) | 0.07 |
| RF | 67 (51–83) | 72 (57–94) | 0.9 | 76 (62–85) | 0.8 | 77 (62–85) | 0.8 | 59 (52–63) | 0.5 | |
| RF/U | 84 (52–110) | 64 (55–88) | 0.1 | 85 (43–138) | 0.7 | 89 (77–122) | 0.8 | 70 (65–75) | 0.4 |
Designation is the same as under Table 3. All continuous variables are expressed as a median and interquartile range [Q1–Q3] as not normally distributed. The Shapiro–Wilk test was used to check if a continuous variable follows a normal distribution. Differences were statistically significant at p < 0.05.